Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMO | Q99835 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030742 | 0.95 | TSHR (0.67) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL2026313 | 0.91 | TSHR (0.64) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL2029168 | 0.90 | SMO (0.65) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL2026830 | 0.86 | TSHR (0.68) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL14300682 | 0.85 | TSHR (0.55) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL2025611 | 0.85 | TSHR (0.72) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL2029400 | 0.83 | TSHR (0.64) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL2031286 | 0.83 | RAB9A (0.65) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL2026741 | 0.83 | TSHR (0.64) | TSHRLMNAHTTRAB9AMEN1 | |
| SCHEMBL2028080 | 0.83 | TSHR (0.67) | TSHRLMNAHTTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | claimed |
| EP-2044064-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2009-04-08 | — | — | EP | claimed |
| WO-2008003861-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2008-01-10 | — | — | WO | claimed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| EP-2044064-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008003861-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | EPX, PGLS, ENPEP | TSHR 2305/4885LMNA 1439/4885HTT 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.